SCHEMBL13097048

SCHEMBL13097048

Cc1ccnc(-c2ccc(N)nc2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.44
NOS2 P35228 1/20 0.44
PIK3CD O00329 2/20 0.43
MKNK1 Q9BUB5 1/20 0.42
MKNK2 Q9HBH9 1/20 0.42
IRAK4 Q9NWZ3 1/20 0.41
MTOR P42345 3/20 0.41
PIK3CA P42336 2/20 0.41
PIK3R1 P27986 1/20 0.41
MAP4K4 O95819 1/20 0.40
MAPKAPK2 P49137 1/20 0.38
TLR9 Q9NR96 2/20 0.38
TLR8 Q9NR97 2/20 0.38
TLR7 Q9NYK1 2/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
TGFBR1 P36897 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8365585 0.83 HPGDS (0.46) PIK3CDPIK3CAMEN1KMT2ANPC1
SCHEMBL6325641 0.79 MEN1 (0.45) IRAK4MEN1KMT2ANPC1RAB9A
SCHEMBL13662709 0.79 IRAK4 (0.47) NOS3NOS2PIK3CDIRAK4MTOR
SCHEMBL13086514 0.78 SMN1; SMN2 (0.40) NOS3NOS2PIK3CDMKNK1MKNK2
SCHEMBL4024239 0.77 PIK3CD (0.52) NOS3NOS2PIK3CDMKNK1MKNK2
SCHEMBL31025875 0.76 PIK3CD (0.56) NOS3NOS2PIK3CDMKNK1MKNK2
SCHEMBL23600957 0.76 CYP2A6 (0.46) PIK3CDMKNK1MKNK2PIK3CANPC1
SCHEMBL15345083 0.76 BACE1 (0.52) IRAK4KDM4E
SCHEMBL2666244 0.75 MEN1 (0.59) MAP4K4MEN1KMT2ANPC1RAB9A
SCHEMBL31186653 0.74 CYP1A1 (0.46) IRAK4MAP4K4MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293769-B2 CSF-1R inhibitors, compositions, and methods of use NOVARTIS AG (CH) 2012-10-23 US disclosed
US-20100261679-A1 CSF-1R, Inhibitors, Compositions, and Methods of Use NOVARTIS AG (CH) 2010-10-14 US disclosed
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE NOVARTIS AG (CH) 2010-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261679-A1 CSF-1R, Inhibitors, Compositions, and Methods of Use CSF1R, CSF3R, MSR1 NOS3 179/4885NOS2 192/4885PIK3CD 3170/4885
US-20100130490-A1 CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE CSF1R, CSF3R, FLT3 NOS3 339/4885NOS2 529/4885PIK3CD 4246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.